Marcus Boehm - Mar 30, 2021 Form 4/A - Amendment Insider Report for Vyant Bio, Inc. (VYNT)

Role
Director
Signature
/s/ Andrew LaFrence, attorney-in-fact
Stock symbol
VYNT
Transactions as of
Mar 30, 2021
Transactions value $
$37,225
Form type
4/A - Amendment
Date filed
7/1/2021, 09:56 PM
Date Of Original Report
Apr 1, 2021
Next filing
Jun 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNT Common Stock, $0.0001 par value Other +93.8K 93.8K Mar 30, 2021 Direct F1
transaction VYNT Common Stock, $0.0001 par value Gift $0 -78.3K -83.69% $0.00 15.3K May 5, 2021 Direct
transaction VYNT Common Stock, $0.0001 par value Gift $0 +78.3K $0.00 78.3K May 5, 2021 By Trust
transaction VYNT Common Stock, $0.0001 par value Gift $0 -15.5K -100% $0.00* 0 May 10, 2021 Direct
transaction VYNT Common Stock, $0.0001 par value Gift $0 +15.5K +19.83% $0.00 93.8K May 10, 2021 By Trust
transaction VYNT Common Stock, $0.0001 par value Purchase $18.4K +5K +5.33% $3.68 98.8K May 28, 2021 By Trust F2, F3
transaction VYNT Common Stock, $0.0001 par value Purchase $18.8K +5K +5.06% $3.76 104K Jun 30, 2021 By Trust F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
F2 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021.
F3 Shares were previously reported as being directly held by reporting person.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Remarks:

This amended Form 4 is being filed to correct (i) the number of shares issued pursuant to the merger on March 30, 2021, (ii) reporting person's indirect purchase of shares (via a trust) on May 28, 2021 and (iii) the disclosure of shares previously owned directly that were transferred to a trust reported on the Form 4 filed July 1, 2021.